News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Start News Corporate Action Shares Issuance

Press releases

Regulatory

May 19, 2022

Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue

Regulatory

March 21, 2022

Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million

Regulatory

November 30, 2020

Change in the number of shares and votes in PledPharma

Regulatory

November 25, 2020

PledPharma raises SEK 250 million in oversubscribed rights issue and utilized overallotment option

Regulatory

October 5, 2020

PledPharma carries out a fully guaranteed rights issue of approximately SEK 200 million in connection with the acquisition of Rare Thyroid Therapeutics

Regulatory

May 21, 2019

PledPharma completes a Directed New Share Issue of 4,866,665 shares, raising proceeds of SEK 91 million

Regulatory

May 21, 2019

PledPharma announces intention of a Directed New Share Issue

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com